| Hidradenitis Suppurativa and Treatments | Lifetime | 6 | IT 1 | 99.02 |
| Autoimmune Bullous Skin Diseases | Lifetime | 56 | IT 4 | 99.26 |
| Autoimmune and Inflammatory Disorders | Lifetime | 35 | IT 2 | 99.24 |
| Urticaria and Related Conditions | Lifetime | 76 | IT 8 | 99.03 |
| Dermatological and COVID-19 studies | Lifetime | 17 | IT 1 | 98.00 |
| Coagulation, Bradykinin, Polyphosphates, and Angioedema | Lifetime | 181 | IT 17 | 98.18 |
| Colorectal and Anal Carcinomas | Lifetime | 258 | IT 10 | 98.18 |
| Oral Health Pathology and Treatment | Lifetime | 217 | IT 9 | 97.95 |
| Eosinophilic Disorders and Syndromes | Lifetime | 303 | IT 28 | 97.65 |
| Cutaneous lymphoproliferative disorders research | Lifetime | 315 | IT 27 | 96.91 |
| Skin Diseases and Diabetes | Lifetime | 119 | IT 9 | 96.48 |
| Chemotherapy-related skin toxicity | Lifetime | 156 | IT 11 | 94.59 |
| Inflammasome and immune disorders | Lifetime | 684 | IT 45 | 94.45 |
| Parvovirus B19 Infection Studies | Lifetime | 488 | IT 29 | 95.18 |
| Dermatological and Skeletal Disorders | Lifetime | 411 | IT 28 | 92.81 |
| Drug-Induced Adverse Reactions | Lifetime | 675 | IT 39 | 92.67 |
| Mast cells and histamine | Lifetime | 984 | IT 57 | 92.53 |
| Histiocytic Disorders and Treatments | Lifetime | 429 | IT 31 | 90.87 |
| Osteomyelitis and Bone Disorders Research | Lifetime | 520 | IT 31 | 77.05 |
| Colorectal and Anal Carcinomas | 2021-2025 | 5 | IT 2 | 99.47 |
| Autoimmune and Inflammatory Disorders | 2021-2025 | 4 | IT 2 | 99.65 |
| Hidradenitis Suppurativa and Treatments | 2021-2025 | 4 | IT 1 | 99.20 |
| Autoimmune Bullous Skin Diseases | 2021-2025 | 18 | IT 1 | 99.10 |
| Urticaria and Related Conditions | 2021-2025 | 29 | IT 2 | 98.52 |
| Dermatology and Skin Diseases | 2021-2025 | 152 | IT 24 | 97.65 |
| Dermatological and COVID-19 studies | 2021-2025 | 19 | IT 8 | 93.67 |
| Cutaneous lymphoproliferative disorders research | 2021-2025 | 112 | IT 19 | 94.63 |
| Coagulation, Bradykinin, Polyphosphates, and Angioedema | 2021-2025 | 119 | IT 12 | 93.84 |
| Psoriasis: Treatment and Pathogenesis | 2021-2025 | 301 | IT 56 | 93.44 |
| Cancer and Skin Lesions | 2021-2025 | 175 | IT 24 | 86.47 |
| Eosinophilic Disorders and Syndromes | 2021-2025 | 289 | IT 47 | 88.80 |
| Microscopic Colitis | 2021-2025 | 637 | IT 78 | 90.48 |
| Chemotherapy-related skin toxicity | 2021-2025 | 62 | IT 7 | 85.51 |
| Allergic Rhinitis and Sensitization | 2021-2025 | 716 | IT 77 | 89.29 |
| Oral Health Pathology and Treatment | 2021-2025 | 341 | IT 43 | 85.82 |
| Inflammasome and immune disorders | 2021-2025 | 760 | IT 41 | 83.78 |
| Nail Diseases and Treatments | 2021-2025 | 334 | IT 19 | 84.96 |
| Nonmelanoma Skin Cancer Studies | 2021-2025 | 564 | IT 77 | 81.26 |
| Dermatological and Skeletal Disorders | 2021-2025 | 197 | IT 38 | 72.95 |
| Drug-Induced Adverse Reactions | 2021-2025 | 576 | IT 50 | 75.66 |
| Parvovirus B19 Infection Studies | 2021-2025 | 405 | IT 43 | 69.98 |
| Hedgehog Signaling Pathway Studies | 2021-2025 | 433 | IT 37 | 63.42 |
| Poxvirus research and outbreaks | 2021-2025 | 1,000 | IT 66 | 63.22 |
| Genetic and rare skin diseases. | 2021-2025 | 464 | IT 48 | 53.03 |
| Skin Diseases and Diabetes | 2021-2025 | 706 | IT 81 | 38.89 |
